CXCL13 and oral cavity squamous cell carcinoma: c-Myc activation through the CXCL13:CXCR5 signaling axis stimulates RANKL expression in stromal/preosteoblast cells, therefore implicating CXCL13 as a potential therapeutic target to prevent oral squamous cell carcinoma invasion of bone/osteolysis (140).